Mirum Pharmaceuticals, Inc. last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $185.7 million (+39.6% year over year) and diluted EPS of -$0.87. It usually reports 12–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
186
+39.6%
|
-41
-1503.3%
|
-0.87
-1840.0%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
176
+37.9%
|
-67
-1047.0%
|
-1.06
-783.3%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
160
+43.3%
|
-790
-5283.6%
|
-13.43
-4376.7%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
149
+49.8%
|
-6
+75.9%
|
-0.11
+77.5%
|
|
Nov 4, 2025
35 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
133
+47.2%
|
3
+120.4%
|
0.05
+116.7%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
128
+64.1%
|
-6
+76.2%
|
-0.12
+76.9%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
112
+61.2%
|
-15
+41.9%
|
-0.30
+44.4%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
99
+42.9%
|
-24
+33.3%
|
-0.49
+64.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIRM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1759425
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.